| meta-analysis | Q815382 |
| scholarly article | Q13442814 |
| P50 | author | Roy M. Anderson | Q7373091 |
| Hugo C. Turner | Q55201881 | ||
| Jaspreet Toor | Q41631169 | ||
| P2860 | cites work | Cost and cost-effectiveness of soil-transmitted helminth treatment programmes: systematic review and research needs | Q26825338 |
| Socioeconomic aspects of neglected tropical diseases | Q28271639 | ||
| National mass drug administration costs for lymphatic filariasis elimination | Q28469337 | ||
| An investigation into the interaction between drug efficacy and drug price of praziquantel in determining the cost-effectiveness of school-targeted treatment for Schistosoma mansoni using a population dynamic model. | Q53353306 | ||
| Cost-effectiveness analysis and capital costs | Q57345505 | ||
| The Costs Of Scaling Up Vaccination In The World’s Poorest Countries | Q58504335 | ||
| Cost-effectiveness analysis and health care resource allocation: decision rules under variable returns to scale | Q64133890 | ||
| Different approaches to modelling the cost-effectiveness of schistosomiasis control | Q77913844 | ||
| Modeling the impact and costs of semiannual mass drug administration for accelerated elimination of lymphatic filariasis | Q28484840 | ||
| Transmission Assessment Surveys (TAS) to Define Endpoints for Lymphatic Filariasis Mass Drug Administration: A Multicenter Evaluation | Q28536142 | ||
| Financial and Economic Costs of the Elimination and Eradication of Onchocerciasis (River Blindness) in Africa | Q28547910 | ||
| Projected benefits from integrating NTD programs in sub-Saharan Africa | Q29398511 | ||
| Neglected tropical diseases: progress towards addressing the chronic pandemic | Q30061948 | ||
| Economic Considerations for Moving beyond the Kato-Katz Technique for Diagnosing Intestinal Parasites As We Move Towards Elimination | Q30236002 | ||
| The potential impact of moxidectin on onchocerciasis elimination in Africa: An economic evaluation based on the Phase II clinical trial data | Q30936469 | ||
| Investment Success in Public Health: An Analysis of the Cost-Effectiveness and Cost-Benefit of the Global Programme to Eliminate Lymphatic Filariasis | Q33603042 | ||
| Cost-effectiveness of triple drug administration (TDA) with praziquantel, ivermectin and albendazole for the prevention of neglected tropical diseases in Nigeria | Q33873632 | ||
| Weekly iron-folic acid supplementation with regular deworming is cost-effective in preventing anaemia in women of reproductive age in Vietnam | Q34023146 | ||
| Reaching the london declaration on neglected tropical diseases goals for onchocerciasis: an economic evaluation of increasing the frequency of ivermectin treatment in Africa | Q34202166 | ||
| Integrated programme for control of geohelminths: a perspective. | Q34315845 | ||
| Does scale matter? The costs of HIV-prevention interventions for commercial sex workers in India. | Q35750673 | ||
| Costs of scaling up health interventions: a systematic review | Q36028973 | ||
| Benchmarking the Cost per Person of Mass Treatment for Selected Neglected Tropical Diseases: An Approach Based on Literature Review and Meta-regression with Web-Based Software Application | Q36213356 | ||
| An economic evaluation of expanding hookworm control strategies to target the whole community | Q36255264 | ||
| A cost function for HIV prevention services: is there a 'u' - shape? | Q36391606 | ||
| A blueprint for success: integration of neglected tropical disease control programmes | Q36483770 | ||
| Cost and cost-effectiveness of nationwide school-based helminth control in Uganda: intra-country variation and effects of scaling-up | Q37087378 | ||
| The economics of scaling up: cost estimation for HIV/AIDS interventions | Q37229654 | ||
| Lymphatic filariasis and onchocerciasis prevention, treatment, and control costs across diverse settings: a systematic review | Q38201974 | ||
| Neglected tools for neglected diseases: mathematical models in economic evaluations | Q38279486 | ||
| Accounting for the cost of scaling-up health interventions | Q38460924 | ||
| Cost-effectiveness of scaling up mass drug administration for the control of soil-transmitted helminths: a comparison of cost function and constant costs analyses | Q38855729 | ||
| Integration of deworming into an existing immunisation and vitamin A supplementation campaign is a highly effective approach to maximise health benefits with minimal cost in Lao PDR. | Q38915764 | ||
| Controlling schistosomiasis: the cost-effectiveness of alternative delivery strategies | Q39038139 | ||
| Control of Ascaris infection by chemotherapy: which is the most cost-effective option? | Q39038156 | ||
| How much will it cost to eradicate lymphatic filariasis? An analysis of the financial and economic costs of intensified efforts against lymphatic filariasis | Q41994054 | ||
| A comparative analysis of the cost-effectiveness of treatment based on parasitological and symptomatic screening for Schistosoma mansoni in Burundi | Q43448955 | ||
| A population dynamic approach to the cost-effectiveness analysis of mass anthelmintic treatment: effects of treatment frequency on Ascaris infection | Q44018266 | ||
| The cost of Child Health Days: a case study of Ethiopia's Enhanced Outreach Strategy (EOS). | Q45745876 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1298-1303 | |
| P577 | publication date | 2018-04-01 | |
| P1433 | published in | Clinical Infectious Diseases | Q5133764 |
| P1476 | title | Economic evaluations of mass drug administration: The importance of economies of scale and scope | |
| P478 | volume | 66 |
| Q55220170 | Are We on Our Way to Achieving the 2020 Goals for Schistosomiasis Morbidity Control Using Current World Health Organization Guidelines? |
| Q90234620 | Economic evaluations of onchocerciasis interventions: a systematic review and research needs |
| Q55281650 | Ensuring no one is left behind: Urgent action required to address implementation challenges for NTD control and elimination. |
| Q92541252 | Modelling the impact of a Schistosoma mansoni vaccine and mass drug administration to achieve morbidity control and transmission elimination |
| Q89751553 | Optimizing the Number of Child Deaths Averted with Mass Azithromycin Distribution |
| Q57182014 | The design of schistosomiasis monitoring and evaluation programmes: The importance of collecting adult data to inform treatment strategies for Schistosoma mansoni |
Search more.